HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beiersdorf/Senetek collaboration

This article was originally published in The Rose Sheet

Executive Summary

Nivea skin care marketer Beiersdorf and Kinetin technology manufacturer Senetek form research agreement allowing Beiersdorf to conduct laboratory and in vivo evaluations of various skin care compounds owned by Senetek, two firms announce June 25. At the conclusion of each evaluation, Beiersdorf will have opportunity to enter licensing agreements to use the compound in its own products in global markets, while Senetek will maintain the right to license the compounds in markets not tapped by Beiersdorf, companies say. Beiersdorf's research and development programs in skin care are focused on protecting the skin from photodamage and treating skin aging, company adds. Senetek's Kinetin anti-aging technology also is used by Revlon and The Body Shop...

You may also be interested in...

Senetek Expects To License Zeatin Technology In 12 To 18 Months

Healthcare technology company Senetek expects to have a new patented anti-aging compound, Zeatin, ready to license to skin care manufacturers within the next 12 to 18 months, Chairman and CEO Frank Massino said, cautioning the timeframe will be directed by the timing of upcoming pre-clinical and clinical efficacy studies

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts